• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macros
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macros
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
Nairametrics
No Result
View All Result
Home Economy Socio Economic
AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19

AstraZeneca Tablets At A Pharmacists As Company Explores Deal With Acerta Pharma...Packets of Nexium, manufactured AstraZeneca Plc, sit on a table at a pharmacists in this arranged photograph in London, U.K., on Monday, Dec. 14, 2015. AstraZeneca Plc said it's exploring a deal with Acerta Pharma BV that would give the U.K. drugmaker a potential blockbuster medicine for blood cancers as well as diseases in which the body attacks itself. Photographer: Simon Dawson/Bloomberg

AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19

Chidinma Anyalewechi by Chidinma Anyalewechi
2 years ago
in Socio Economic
Share on FacebookShare on TwitterShare on Linkedin

In a late-stage study, AstraZeneca’s experimental Covid-19 antibody drug cocktail has succeeded in reducing severe disease or death in non-hospitalized patients, the British drugmaker said on Monday.

Similar to the results obtained with the Merck antiviral pills, the Astrazeneca drug, called AZD7442, has proven to reduce the risk of developing severe Covid-19 or death by 50%, in patients who had been symptomatic for seven days or less, meeting the main goal of the trial, according to CNBC.

The success of this drug cocktail and the Merck antiviral pills have been described as a huge breakthrough, considering the devastating effect the Coronavirus has had on the global space this time last year.

What they are saying

The executive vice president, biopharmaceuticals R&D at AstraZeneca, Mene Pangalos, said, “an early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months.”

He further stated that the company will discuss all available data with health authorities.

The drugmaker has requested emergency approval of its drug cocktail from U.S regulators for its use as a prevention drug last week. The drug cocktail is also being developed to serve as a therapy to protect people who do not have a strong enough immune response to Covid-19 vaccines.

In addition, AstraZeneca’s therapy is the first of its kind to show positive potential as preventative medicine and as a treatment for COVID-19 following multiple trials and these therapies have been approved for emergency use in the United States for treating mild-to-moderate COVID-19.

The trial Principal investigator, Hugh Montgomery said in a statement that, “These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic”.

Tags: AstraZenecaAZD7442Covid-19
Chidinma Anyalewechi

Chidinma Anyalewechi

For further inquiries about this article, contact: Email: chidinma.anyalewechi@nairametrics.com LinkedIn: linkedin.com/in/chidinma-anyalewechi-a323ab173/

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *







NM newsletters
Glo
Kwakol
Abbey
Zenth Bank
UBA
Mega Millions

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • Naira sustains freefall as NAFEM closing rate drops by 11.39% to hits N927.19/$ 
  • The top 5 largest food companies in Nigeria based on revenue in 2023 
  • Falcon Corporation Limited secures N19.41 billion debt facility from Chapel Hill Denham Nigeria Infrastructure Debt Fund

Follow us on social media:

Recent News

Naira, Dollar

Naira sustains freefall as NAFEM closing rate drops by 11.39% to hits N927.19/$ 

December 1, 2023
Nestle

The top 5 largest food companies in Nigeria based on revenue in 2023 

December 1, 2023
  • Download Nairametrics iOS App
  • Download Nairametrics Android App
  • Contact Us
  • Home
  • Markets
  • Sectors
  • Economy
  • Business News
  • Financial Literacy
  • Disclaimer
  • Ads Disclaimer

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macros
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • Login
  • Sign Up

© 2023 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In